Baxalta, a biopharmeceutical company that specializes in treating rare conditions, was spun off from the healthcare giant Baxter International (ranked No. 286 on this year's Forutne 500) last July. Earning $6.1 billion in revenue its inaugural year, the young company is looking forward to greater growth as it awaits the conclusion of a $32 billion merger with Shire.
Company Info
| CEO | Ludwig N. Hantson |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | Bannockburn, IL |
| Website | www.baxalta.com |
| Years on Fortune 500 List | 1 |
| Employees | 17,000 |
Key Financials (last fiscal year)
| Revenues ($M) | $6,149 |
| Profits ($M) | $956 |
| Assets ($M) | $12,329 |
| Total Stockholder Equity ($M) | $3,924 |
| Market Value — as of March 31, 2016 ($M) | $27,522 |
Profit Ratios
| Profit as % of Revenues | 15.5% |
| Profits as % of Assets | 7.8% |
| Profits as % of Stockholder Equity | 24.4% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 14 |
| EPS % Change (from 2014) | - |
| EPS % Change (5 year annual rate) | - |
| EPS % Change (10 year annual rate) | - |
Total Return
| Total Return to Investors (2015) | - |
| Total Return to Investors (5 year, annualized) | - |
| Total Return to Investors (10 year, annualized) | - |
